Due to the wide range of biological pathways, gene silencing of SOD1 is currently in clinical trials as a therapeutic strategy for SOD1-ALS patients (van Zundert and Brown, 2017). The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.